The honest answer: for most healthy women who are under 60 or within 10 years of their last period and have symptoms that bother them, hormone therapy's benefits generally outweigh its risks[1] — but "worth it" is a personal calculation, not a slogan. HRT is the most effective treatment we have for hot flashes, night sweats, and vaginal symptoms, and it slows bone loss. It is not a longevity drug, and it is not for everyone. This page lays out what it treats well, the risks in real numbers, what it actually costs in 2026, and how to decide.
Quick verdict — is it worth it, and in what form?
- Best value Generic estradiol (pill or weekly patch), plus micronized progesterone if you still have a uterus. FDA-approved, decades of data, usually the cheapest route.
- Lower clot risk Transdermal estrogen (patch or gel) skips the first pass through the liver and is generally linked to lower clot and stroke risk than pills — often the better pick if you have risk factors.
- Vaginal only Low-dose vaginal estrogen for dryness, painful sex, or recurrent UTIs. Barely enters the bloodstream, very low risk, inexpensive as a generic.
- Non-hormonal Fezolinetant (Veozah) for hot flashes if estrogen is off the table. Proven and FDA-approved — but pricey, with no generic yet.
- Skip Compounded "bioidentical" pellets and creams marketed as safer or "natural." Not FDA-approved, not shown to be safer, and often cost more.
How we approached this — and what we don't do
We are a publisher, not a pharmacy or a hormone clinic. We don't sell HRT, we don't crown a single "best brand," and we don't run testimonials we haven't verified. Everything below is drawn from published guidelines (The Menopause Society, ACOG, USPSTF), the FDA, and the Women's Health Initiative trials. Prices are ranges as of 2026 and vary by pharmacy, location, dose, and insurance — always check your own plan. None of this is a prescription; it's context to make the conversation with your clinician sharper.
What does HRT actually cost in 2026?
Cost is where a lot of the "worth it" question really lives — and it swings enormously depending on whether you use an FDA-approved generic or a brand-name or compounded product. The single biggest money-saver is choosing generic estradiol, which most insurance plans cover.[6] The table below shows realistic ranges; treat them as ballpark, not quotes.
| Option | Form | Rough cost without insurance | FDA status & notes |
|---|---|---|---|
| Generic estradiol (systemic) | Pill or weekly patch | ~$10–30/mo (pill); ~$30–150/mo (patch) | FDA-approved; commonly covered; coupons can cut cost further |
| Micronized progesterone | Oral capsule | ~$10–40/mo | FDA-approved; needed to protect the uterine lining if you have a uterus |
| Low-dose vaginal estrogen | Cream, tablet, or ring | ~$30–80/mo equivalent (generic cream cheapest) | FDA-approved; minimal blood absorption; brand inserts pricier |
| Brand-name / combination products | Patch or pill | ~$100–250+/mo | FDA-approved; often placed on high insurance tiers |
| Fezolinetant (Veozah) — non-hormonal | Daily pill | ~$550–765/mo | FDA-approved (2023); no generic; manufacturer savings card for insured patients |
| Compounded "bioidentical" | Pellets, creams, troches | ~$75–300+/mo, rarely covered | Not FDA-approved; not shown to be safer or more effective |
| Telehealth menopause visit | Video consult | ~$20–75/visit with insurance; ~$35–49/mo or ~$200/visit self-pay | Model varies by company; verify current pricing and whether meds are extra |
Insurance changes the picture for most people: generic estradiol is on the vast majority of Medicare, Medicaid, and commercial formularies, with copays that often run single digits to about $50. Brand-name and compounded products are where surprise bills happen. To model your own numbers, our cost & coverage estimator walks through generic-vs-brand and with-vs-without-insurance scenarios, and our deeper dives on what HRT costs and whether insurance covers it cover the fine print.
What are the proven benefits?
This is the strong side of the ledger, and it's genuinely strong. Three benefits are well supported:
- Hot flashes and night sweats (vasomotor symptoms). Systemic estrogen is the most effective treatment available, typically cutting the frequency and severity of hot flashes substantially. For many women this is the whole reason to consider it — see our guide to managing hot flashes.
- Genitourinary syndrome of menopause (GSM). Vaginal dryness, painful sex, and recurrent urinary symptoms respond very well to low-dose vaginal estrogen, which acts locally with minimal absorption into the bloodstream. It can even be an option for some women who can't use systemic hormones.[5]
- Bone loss and fractures. Estrogen slows the accelerated bone loss of early menopause and reduces fractures, including at the hip. It's FDA-approved for preventing osteoporosis, though guidelines reserve that as a primary reason mainly for women who also have symptoms or can't take other bone drugs.
One thing HRT is not for: taking it purely to prevent heart disease or dementia. The USPSTF recommends against using hormone therapy solely to prevent chronic conditions, and no major society endorses it for heart-disease prevention.[2] If someone is selling HRT as anti-aging insurance, that's marketing outrunning the evidence.
What are the real risks — in absolute numbers?
The scary 2002 headlines came from the Women's Health Initiative (WHI), and they were reported as relative risks ("26% more breast cancer"), which sounds alarming. The honest way to read risk is in absolute numbers — how many extra events per 10,000 women per year. Here is what the combined estrogen-plus-progestin arm actually showed, in a group whose average age was 63 — older than the typical woman starting HRT today.
| Outcome | Direction | In plain numbers (per 10,000 women/year) |
|---|---|---|
| Invasive breast cancer | Higher | about 8 more |
| Coronary heart disease | Higher | about 7 more |
| Stroke | Higher | about 8 more |
| Blood clots in the lungs | Higher | about 8 more |
| Hip fracture | Lower | about 5 fewer |
| Colorectal cancer | Lower | about 6 fewer |
A few points that change how "worth it" this looks:[1]
- Timing matters. These absolute risks are smaller for women who start under 60 or within 10 years of menopause — the exact window where guidelines say the balance is favorable. Starting a decade or more out, or after 60, tilts the balance the other way.
- Estrogen alone is different. Women who'd had a hysterectomy and took estrogen without progestin did not have more breast cancer in the WHI — and in long-term follow-up had slightly less. The breast-cancer signal is tied mainly to the added progestogen and to duration of use. Our piece on HRT and breast cancer risk unpacks this.
- Route matters. Transdermal estrogen appears to carry less clot and stroke risk than oral, which is why it's often preferred when there are risk factors. See pills vs. patches vs. gels.
In November 2025 the FDA began removing the decades-old boxed "black box" warning from menopause hormone therapy, calling the original interpretation of WHI data outdated — though it kept a warning about endometrial cancer for estrogen-alone products used by women who still have a uterus.[3] That's why women with a uterus take a progestogen alongside estrogen: it protects the uterine lining. For the wider safety picture, see is HRT safe.
Who is HRT not for?
Systemic estrogen is generally not appropriate — or needs a specialist's careful case-by-case judgment — if you have:[4]
- A personal history of hormone-sensitive (estrogen-receptor-positive) breast cancer
- A history of blood clots (deep vein thrombosis or pulmonary embolism) or a clotting disorder
- A history of stroke, TIA, or a recent heart attack
- Unexplained vaginal bleeding that hasn't been evaluated
- Active liver disease
- Known or suspected pregnancy
Even here, options exist. Low-dose vaginal estrogen for GSM and non-hormonal treatments like fezolinetant for hot flashes can be on the table when systemic hormones aren't. And a common worry — weight — is largely a myth: the evidence does not show HRT itself causes weight gain, as we cover in does HRT cause weight gain.
A simple way to decide if it's worth it
Rather than a yes/no verdict, run your own numbers through four honest questions:
- How much are symptoms costing you? Broken sleep, drenching night sweats, brain fog, painful sex — if these are eroding your daily life, the benefit side is large. If symptoms are mild, the math is closer.
- Where are you in the timeline? Under 60 or within 10 years of your last period is the favorable window. Further out, the risk-benefit balance shifts and deserves more scrutiny.
- What's your personal risk profile? Clot, stroke, and hormone-sensitive-cancer history move the needle. Route (patch vs. pill) and using vaginal-only estrogen can lower risk.
- What can you afford, sustainably? A generic that costs $15 a month is a very different commitment than a $550 non-hormonal drug or a cash-pay compounding subscription.
Walk into the appointment prepared: our questions to ask your doctor about HRT and the wider menopause hub can help you frame it. The goal isn't to talk yourself into or out of hormones — it's to make a decision that fits your body, your symptoms, and your budget.
What the pooled evidence actually found
Almost every strong claim about HRT — that it protects the heart, that it causes breast cancer, that it is safe if you start early — can be supported by picking one trial and ignoring the rest. The trials disagree because they enrolled different women. The Women's Health Initiative recruited women whose average age was well past 60, many of them more than a decade past their last period; smaller trials recruited women in their early fifties. Pooled reviews are useful precisely because they force those trials into one place and then ask whether the disagreement is real signal or noise.
Three reviews carry most of the weight for the benefit-risk question, and they were read in full for this section rather than summarised from secondary sources.
The Cochrane review by Boardman and colleagues[s1] pooled 19 randomised trials and 40,410 post-menopausal women. Taken as one undifferentiated group, hormone therapy did nothing for survival: all-cause mortality RR 1.00, cardiovascular death RR 0.81 (95% CI 0.47–1.40), non-fatal heart attack RR 1.02 (0.80–1.31). It did raise stroke (RR 1.24, 1.10–1.41) and venous thromboembolism (RR 1.92, 1.36–2.69). In absolute terms Cochrane put those at roughly 6 extra strokes and 8 extra clots per 1,000 women treated. Then the review split the trials by time since menopause, and the picture changed. Among women who started within 10 years of menopause, all-cause mortality was RR 0.70 and coronary heart disease RR 0.52. Among those starting 10 or more years out, mortality RR 1.06 (0.95–1.18) and CHD RR 1.07 (0.96–1.20) — nothing — while stroke (RR 1.21, 1.06–1.38) and clot risk (RR 1.96, 1.37–2.80) stayed up.
Nudy, Chinchilli and Foy[s2] pooled 31 trials and 40,521 participants specifically to test that timing hypothesis, and found the same split for mortality: OR 0.72 (0.57–0.91) in trials of younger initiators versus OR 1.08 (0.97–1.21) in older ones, with the difference between groups statistically significant. But their most important finding is the one that cuts against the optimistic reading. Stroke, TIA and systemic embolism were raised in both groups — OR 1.40 (1.10–1.78) in younger initiators, OR 1.52 (1.39–1.71) in older — with no evidence of heterogeneity between them. Starting early does not appear to buy you out of the clot-and-stroke risk.
The second Cochrane review, by Marjoribanks and colleagues[s3], pooled 22 studies and 43,637 women and reported everything as natural frequencies, which is the format a person deciding actually needs. Its blunt conclusion: fracture was the only outcome for which strong evidence showed clinical benefit.
| Outcome | Without HT | On continuous combined HT | Does timing change it? |
|---|---|---|---|
| Clinical fracture (5.6 yrs) | 111 | 79–96 | Benefit not shown to depend on timing; strongest evidence of benefit in the review[s3] |
| Breast cancer (5.6 yrs) | 19 | 20–30 | Not stratified by timing. With oestrogen-only HT over 7 years, 25 without vs 15–25 on treatment — no increase[s3] |
| Venous thromboembolism (1 yr) | 2 | 4–11 | Yes and no — still raised in early starters (RR 1.74), but in women aged 50–59 the absolute risk stayed below 1 in 500[s1][s3] |
| Stroke (3 yrs) | 6 | 6–12[s3] | Barely. Raised in early and late starters, no evidence of a difference between age groups (I² = 0%)[s2] |
| Coronary heart disease | 2 events/1,000 in yr 1 | 3–7 in yr 1[s3] | Yes, strongly. RR 0.52 if started <10 yrs post-menopause; RR 1.07 (0.96–1.20) if ≥10 yrs[s1] |
| All-cause mortality | No overall effect: RR 1.00 | Yes. RR 0.70 started <10 yrs out; RR 1.06 (0.95–1.18) started ≥10 yrs out[s1] | |
| Gallbladder disease (5.6 yrs) | 27 | 38–60 | Not reported by timing[s3] |
The honest bottom line for someone weighing the cost: the pooled evidence supports timing as a real modifier for mortality and heart disease, and it supports fracture reduction as a genuine benefit — but it does not support HRT as a prevention drug, and it does not show that starting early removes the clot and stroke risk. The absolute numbers are small either way; for a woman in her fifties the excess risks are on the order of a few events per thousand, which is why the trade-off is a personal one rather than an obvious one.
Where the evidence is genuinely weak, and where you should distrust anyone who sounds certain: roughly 70% of the Marjoribanks data came from just two trials, HERS and WHI, and only about 30% of the pooled women were aged 50–59 at baseline — the exact group most likely to be making this decision. The Cochrane cardiovascular review says the same thing, that the majority of enrolled women were over 60. Nudy's team had to sort trials into "younger" and "older" by each trial's average baseline age because age-specific subgroup data were unavailable for most trials, notes many endpoints were likely self-reported rather than formally adjudicated, and reports that the cardiac mortality benefit disappeared once open-label trials were excluded — so even the favourable half of the timing story is less solid than it first looks. Every formulation and route was pooled together, so these numbers cannot tell you whether transdermal differs from oral, or whether micronised progesterone differs from the synthetic progestins used in the old trials — a question that matters a great deal and that the pooled trial evidence simply does not answer. None of these reviews quantifies symptom relief in the same absolute framework, so the benefit that most women are actually buying is the one the pooled safety literature measures least well. This is reference material, not a recommendation; the decision belongs with you and a clinician who knows your history.
When to see a doctor
HRT is a prescription decision, so a clinician — ideally one comfortable with menopause care — should confirm it's right for you. See someone promptly if you have bleeding after menopause, a new breast lump, chest pain, leg swelling or calf pain, or sudden shortness of breath, whether or not you're on hormones. You generally do not need blood hormone testing before starting HRT for symptoms; the diagnosis is usually clinical, based on your age and symptoms.